Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia

doi:10.5246/jcps.2022.05.029

Abstract

Abstract:

The incidence of refractory mycoplasma pneumoniae pneumonia (RMPP) in children is increasing year by year, and the disease is progressing rapidly. It is accompanied by serious complications and legacy effects, seriously affecting the quality of life of children. The selection, dosage, and course of anti-MP drugs in children with RMPP have brought a lot of troubles to pediatric hospitals. In the present study, the characteristics, usage and dosage, drug resistance mechanism, and treatment progress of anti-MP drugs for the treatment of RMPP in children were reviewed. Collectively, our findings provided ideas for the treatment of children with RMPP using anti-MP drugs.

Key words: Children, Refractory mycoplasma pneumonia, Anti-mycoplasma drugs, Treatment, Progression

Supporting:

Haiyan Wu, Xiang Zhang, Shanshan Ding, Guohua Zhang, Linlin Tang, Lin Tang. Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 334-342.

Figures/Tables 2

References 48

[1]	Ni, X. Dignosis and treatment guideline of community acquired pneumonia in children. Clin. Educ. Gen. Pract. 2019, 09, 771–777.
[2]	Chen, Z.M.; Shang, Y.X.; Zhao, S.Y.; Xin, D.L.; Xu, B.P.; Zeng, Y.J.; Lu, M. Zhang, H.L.; Bao, J. Expert consensus on diagnosis and treatment of mycoplasma pneumoniae pneumonia in children. J. Appl. Clin. Pediatr. 2015, 17, 1304–1308.
[3]	Cao, B.; Qu, J.X.; Yin, Y.D.; Eldere, J.V. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin. Respir. J. 2017, 11, 419–429.
[4]	Yamazaki, T.; Kenri, T. Epidemiology of mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front. Microbiol. 2016, 7, 693.
[5]	Gong, C.H.; Liu, F. Mycoplasma pneumoniae pneumonia in children: a clinical analysis of 293 cases. J. Tongji Univ (Med. Sci.). 2020, 41, 331–337.
[6]	Han, X.H. Treatment of refractory mycoplasma pneumoniae pneumonia in children. Med. Philos. B. 2018, 39, 12–15.
[7]	Liu, X.M.; Jing, S.J. Research progress on risk factors related to refractory Mycoplasma pneumoniae pneumonia. China Mod. Med. 2020, 03, 12–16.
[8]	Zhang, W.C.; Zhao, M.C.; Feng, Z.S.; Li, M.; Guo, Y.H.; Li, G.X. The clinical value of pellet agglutination assay for MP antibody titer and colloidal gold method for simultaneously detection of MP-IgM and MP-IgG in children with mycoplasma pneumonia. J. Hebei Med. Univ. 2018, 39, 1058–1061, 1066.
[9]	Wang, H.; Zhao, S.Y. Research progress in pathogenesis, diagnosis and treatment of mycoplasma pneumoniae pneumonia in children. World Clin. Drugs. 2020, 5, 390–398.
[10]	Li, S.L.; Sun, H.M. Progress in global drug resistance patterns and drug resistance mechanisms of mycoplasma pneumoniae. Chin. J. Microbiol. Immunol. 2018, 5, 5395–5400.
[11]	Cao, B.; Zhao, C.J.; Yin, Y.D.; Zhao, F.; Song, S.F.; Bai, L.; Zhang, J.Z.; Liu, Y.M.; Zhang, Y.Y.; Wang, H.; Wang, C. High prevalence of macrolide resistance in mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin. Infect. Dis. 2010, 51, 189–194.
[12]	Waites, K.B. What’s new in diagnostic testing and treatment approaches for Mycoplasma pneumoniae infections in children? Adv. Exp. Med. Biol. 2011, 719, 47–57.
[13]	Atkinson, T.P.; Waites, K.B. Mycoplasma pneumoniae infections in childhood. Pediatr. Infect. Dis. J. 2014, 33, 92–94.
[14]	Zhou, P.X.; Zhou, W.; Wang, X.L.; Zhang, X.L.; Xu, B.P.; Tong, X.M.; Shen, K.L.; Zhai, S.D. Expert consensus on rapid advice guideline for intravenous azithromycin in children. Clin. Med. J. 2019, 17, 39–45.
[15]	Tang, J.Y.; Wang, Q.; Wu, S.J.; Xu, H.P.; Zhang, S.H.; Zhang, G. Efficacy and safety of different-course intravenous azithromycin treatments for mycoplasma pneumonia in children Meta-analysis. China Pharmacist. 2020, 1, 97–100.
[16]	Zheng, Y.; Liu, S.P.; Xu, B.P.; Shi, Z.R.; Wang, K.; Yang, J.B.; Huang, X.; Tang, B.H.; Chen, X.K.; Shi, H.Y.; Zhou, Y.; Wu, Y.E.; Qi, H.; Jacqz-Aigrain, E.; Shen, A.D.; Zhao, W. Population pharmacokinetics and dosing optimization of azithromycin in children with community-acquired pneumonia. Antimicrob. Agents Chemother. 2018, 62, 9.
[17]	Lin, J.T.; Zhang, Y.M.; Wang, C.Z.; Zhou, X.; Huang, M.; Liu, C.T.; Wu, C.G.; Wan, H.Y.; Yu, W.C.; Dai, Y.R. Antibacterial external action of macrolides and expert consensus on clinical application. Chin. J. Internal. Med. 2017, 7, 546–557.
[18]	DiNicolantonio, J.J. Azithromycin for prevention of exacerbations of COPD. N Engl J. Med. 2011, 365, 2235.
[19]	He, W.C.; Zhang, X.J.; Wang, S. Clinical analysis of the combination of modified Huanglian Jiedu Decoction and erythromycin in the treatment of refractory mycoplasma pneumonia. Jilin Med. J. 2020, 12, 2955–2957.
[20]	He, W.C.; Zhang, X.J.; Zhang, W.J. Observation on the therapeutic effect of Qingrejiedu Decoction combined with erythromycin on refractory mycoplasma pneumonia in children. Mod. J. Integr. Tradit. Chin. West. Med. 2020, 20, 2198–2202.
[21]	Liang, Y.T.; Li, L.; Xu, G.M. Clinical effect analysis of low dose methylprednisolone sodium succinate combined with erythromycin in the treatment of children with refractory mycoplasma pneumonia. J. North Pharm. 2020, 07, 92–93.
[22]	Dai, X.Q. Evaluation of Glucocorticoid-assisted Injection of Erythromycin Lactate in the Treatment of Refractory Mycoplasma Pneumoniae Pneumonia in Children. World Latest Med. Inf. 2019, A3, 42–43.
[23]	Han, X.; Miao, N.Y.; Wen, H.M.; Wang, C.H. Minocycline in children with macrolide-resistant mycoplasma pneumoniae pneumonia. J. Pediatr. Pharm. 2016, 22, 17–19.
[24]	Wang, Y.X.; Chu, D.M.; Yao, L.; Wang, B.L. Therapeutic effect of minocycline combined with methylprednisolone sodium succinate in the treatment of refractory mycoplasma pneumoniae pneumonia. Shandong Med. J. 2013, 44, 52–53.
[25]	Chen, Z.M.; Zhao, Y.S.; Wang, Y.S.; Lu, Q.; Zheng, Y.J.; Liu, Y.; Lu, J.R.; Yang, D.H. Some problems of mycoplasma pneumoniae infection. Chin. J. Pediatr. 2016, 02, 84–87.
[26]	Korean Centers for Disease Control and Prevention, Korean National Institute of Health. Korean Antimicrobial Resistance Monitoring System annual report. Chungbuk: The Centers. 2011.
[27]	Chen, Y.; Xue, F.; Zhang, Y.F. Clinical observation of minocycline adjuvant therapy for refractory mycoplasma pneumoniae pneumonia. J. Clin. Pediatr. 2012, 8, 795.
[28]	Infectious Diseases Committee of China Medical Education Association. Expert consensus on clinical application of antimicrobial pharmacokinetic/pharmacodynamics theory. Chin. J. Union Respiration. 2018, 6, 409–446.
[29]	Product Information: MINOCIN(R) oral suspension, minocycline hcl oral suspension. Triax Pharmaceuticals, LLC, Cranford, NJ. 2010.
[30]	Product Information: minocycline HCl oral tablets, minocycline HCl oral tablets. Par Pharmaceutical Companies, Inc. (per Manufacturer), Spring Valley, NY. 2011.
[31]	Product Information: MINOCIN(R) pellet-filled oral capsules, minocycline hcl pellet-filled oral capsules. Triax Pharmaceuticals, LLC, Cranfrod, NJ. 2010.
[32]	Yang, X.; Qin, X.G.; Xin, D.L. The clinical analysis of the minocycline hydrochloride treatment for children with mycoplasmal pneumonia. Chin. Med. Rec. 2013, 14, 64–66.
[33]	Duan, L.F.; Zhou, J. Medication consultation on minocycline administration in a 4-year-old with refractory Mycoplasma pneumoniae and literature review. Cent. South Pharm. 2020, 11, 1928–1931.
[34]	Zeng, N.; Wang, X.J.; Sun, H.J. Safety analysis of minocycline in the treatment of refractory mycoplasma pneumoniae pneumonia in children. Pharm. Care Res. 2020, 20, 137–139.
[35]	Okada, T.; Morozumi, M.; Tajima, T.; Hasegawa, M.; Sakata, H.; Ohnari, S.; Chiba, N.; Iwata, S.; Ubukata, K. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin. Infect. Dis. 2012, 55, 1642–1649.
[36]	Yang, H.J. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J. Pediatr. 2019, 62, 199–205.
[37]	Zeng, N.; Wang, X.J.; Sun, H.J. Safety analysis of minocycline in the treatment of refractory Mycoplasma pneumoniae pneumonia in children. Pharm. Care Res. 2020, 20, 137–139.
[38]	Wu, J.Y.; Sun, S.M. Expert consensus on the use of fluoroquinolones in children. Pharm. Today. 2018, 01, 1–10.
[39]	Guiding Principles of Clinical Application of Antibacterial Agents (2015 Edition), Beijing: People’s Health Publishing House. 2015, 57.
[40]	Jiang, Z.F.; Shen, K.L.; Shen, Y.; Zhu, F.T. Practical Pediatrics. 8th Edition. Beijing: People’s Medical Publishing House. 2015.
[41]	Averbuch, D.; Hidalgo-Grass, C.; Moses, A.E.; Engelhard, D.; Nir-Paz, R. Macrolide resistance in mycoplasma pneumoniae, Israel, 2010. Emerg. Infect. Dis. 2011, 17, 1079–1082.
[42]	Cardinale, F.; Chironna, M.; Dumke, R.; Binetti, A.; Daleno, C.; Sallustio, A.; Valzano, A.; Esposito, S. Macrolide-resistant mycoplasma pneumoniae in paediatric pneumonia. Eur. Respir. J. 2011, 37, 1522–1524.
[43]	Lin, M.; Shi, L.; Huang, A.; Liang, D.; Ge, L.; Jin, Y. Efficacy of levofloxacin on macrolide-unresponsive and corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children. Ann. Palliat. Med. 2019, 8, 632–639.
[44]	Dai, F.F.; Liu, F.Q.; Chen, X.; Yang, J.; Wang, K.; Guo, C.Y. The treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. J. Clin. Pharm. Ther. 2021, 46, 705–710.
[45]	Liang, S.J. Clinical effect analysis of quinolones in the treatment of children with refractory mycoplasma pneumoniae pneumonia and its effect on immune function. Shenyang: China Med. Univ. 2020.
[46]	Liu, L.M.; Yuan, Y.H.; Xie, M.Y.; Gu, R.; Zhao, X.D. Musculoskeletal adverse drug events of levaquin in children: a systematic review. Chin. J. Evid. Based Pediatr. 2015, 10, 193–197.
[47]	Bradley, J.S.; Kauffman, R.E.; Balis, D.A.; Duffy, C.M.; Gerbino, P.G.; Maldonado, S.D.; Noel, G.J. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014, 134, e146–e153.
[48]	Patel, K.; Goldman, J.L. Safety concerns surrounding quinolone use in children. J. Clin. Pharmacol. 2016, 56, 1060–1075.